Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE final guidance disappoints Novartis

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, has published several sets of final and binding guidance on a range of drugs, including Novartis' Jakavi (ruxolitinib). The firm is unimpressed with the negative guidance and wants an early review.

You may also be interested in...



Will The COVID-19 Pandemic Shake Up Access To Medicines?

Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.

Isatuximab EU Approval Decision Due

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.

Countries Consider Pandemic Pooling of Rights And Compulsory Licensing

Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC021857

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel